Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.

Houston Methodist researchers have identified a key protein as a potential therapeutic target for stopping the body's immune ...

Antimicrobials, vaccinations, and anti-inflammatory drugs were associated with a reduced risk of dementia in a systematic ...

KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...

Non-invasive diagnostic model for primary Sjögren’s disease combines salivary biomarkers, serum autoantibodies, and ...

Scientists at the Garvan Institute of Medical Research have discovered how a viral infection causes autoimmune disease, disproving a long-standing theory and opening a promising new approach to ...

Researchers have uncovered how chronic hepatitis C infection leads to autoimmune disease, which opens new paths for treatments ...

Discover a non-invasive diagnostic model for primary Sjögren’s disease using salivary biomarkers, serum autoantibodies, and ...

Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that ...